Stock Track | Natera Soars 16.47% in After-Hours Trading on Q2 Earnings Beat and Raised 2026 Revenue Guidance

Stock Track08-07

Shares of Natera (NTRA) surged 16.47% in post-market trading Thursday, following the release of its second-quarter financial results. The genetic testing company reported a narrower-than-expected loss and revenue that significantly exceeded analyst forecasts.

Natera posted Q2 revenue of $752.8 million, a 38% year-over-year increase, beating the consensus estimate of $660.7 million. The adjusted loss per share was $0.47, outperforming the expected loss of $0.49. The company also raised its full-year 2026 revenue guidance to a range of $2.85 billion to $2.91 billion, up from the previous $2.74 billion to $2.82 billion, and above the Wall Street estimate of $2.80 billion. Management cited higher overall test volumes, particularly a 57% surge in oncology test volumes, as a key driver of the strong performance.

The positive market reaction underscores investor confidence in Natera's growth trajectory. The company highlighted continued progress in reducing the cost of revenues, contributing to improved gross margins, and provided an outlook for positive cash flow in 2026. The after-hours rally reflects robust quarterly execution and an optimistic financial forecast.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1103212829?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 04:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1103212829","market":"us","top_or_hot":-1,"title":"Stock Track | Natera Soars 16.47% in After-Hours Trading on Q2 Earnings Beat and Raised 2026 Revenue Guidance","media":"Stock Track","content":"<p>Shares of Natera (NTRA) surged 16.47% in post-market trading Thursday, following the release of its second-quarter financial results. The genetic testing company reported a narrower-than-expected loss and revenue that significantly exceeded analyst forecasts.</p>\n<p>Natera posted Q2 revenue of $752.8 million, a 38% year-over-year increase, beating the consensus estimate of $660.7 million. The adjusted loss per share was $0.47, outperforming the expected loss of $0.49. The company also raised its full-year 2026 revenue guidance to a range of $2.85 billion to $2.91 billion, up from the previous $2.74 billion to $2.82 billion, and above the Wall Street estimate of $2.80 billion. Management cited higher overall test volumes, particularly a 57% surge in oncology test volumes, as a key driver of the strong performance.</p>\n<p>The positive market reaction underscores investor confidence in Natera's growth trajectory. The company highlighted continued progress in reducing the cost of revenues, contributing to improved gross margins, and provided an outlook for positive cash flow in 2026. The after-hours rally reflects robust quarterly execution and an optimistic financial forecast.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Natera Soars 16.47% in After-Hours Trading on Q2 Earnings Beat and Raised 2026 Revenue Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Natera Soars 16.47% in After-Hours Trading on Q2 Earnings Beat and Raised 2026 Revenue Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-08-07 04:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Natera (NTRA) surged 16.47% in post-market trading Thursday, following the release of its second-quarter financial results. The genetic testing company reported a narrower-than-expected loss and revenue that significantly exceeded analyst forecasts.</p>\n<p>Natera posted Q2 revenue of $752.8 million, a 38% year-over-year increase, beating the consensus estimate of $660.7 million. The adjusted loss per share was $0.47, outperforming the expected loss of $0.49. The company also raised its full-year 2026 revenue guidance to a range of $2.85 billion to $2.91 billion, up from the previous $2.74 billion to $2.82 billion, and above the Wall Street estimate of $2.80 billion. Management cited higher overall test volumes, particularly a 57% surge in oncology test volumes, as a key driver of the strong performance.</p>\n<p>The positive market reaction underscores investor confidence in Natera's growth trajectory. The company highlighted continued progress in reducing the cost of revenues, contributing to improved gross margins, and provided an outlook for positive cash flow in 2026. The after-hours rally reflects robust quarterly execution and an optimistic financial forecast.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NTRA","symbol_name":"Natera, Inc.","start_time":0,"source_url":"","article_id":"1103212829","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1103212829","pubTimestamp":1786048595,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Natera (NTRA) surged 16.47% in post-market trading Thursday, following the release of its second-quarter financial results. The genetic testing company reported a narrower-than-expected...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NTRA":"Natera, Inc."},"translate_title":"股票跟踪 | Natera 第二季度盈利超出预期，盘后交易中股价飙升 16.47%，并上调 2026 年收入指引","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NTRA":1},"content_text":"Shares of Natera (NTRA) surged 16.47% in post-market trading Thursday, following the release of its second-quarter financial results. The genetic testing company reported a narrower-than-expected loss and revenue that significantly exceeded analyst forecasts.\nNatera posted Q2 revenue of $752.8 million, a 38% year-over-year increase, beating the consensus estimate of $660.7 million. The adjusted loss per share was $0.47, outperforming the expected loss of $0.49. The company also raised its full-year 2026 revenue guidance to a range of $2.85 billion to $2.91 billion, up from the previous $2.74 billion to $2.82 billion, and above the Wall Street estimate of $2.80 billion. Management cited higher overall test volumes, particularly a 57% surge in oncology test volumes, as a key driver of the strong performance.\nThe positive market reaction underscores investor confidence in Natera's growth trajectory. The company highlighted continued progress in reducing the cost of revenues, contributing to improved gross margins, and provided an outlook for positive cash flow in 2026. The after-hours rally reflects robust quarterly execution and an optimistic financial forecast.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1103212829","isCrawlerRequest":true}